Company News

We’re honored to have Alexandra Pichard Nielsen, Vice President for Business Development at Porton Pharma Solutions Ltd., join us at BOS Basel 2023! We are excited to witness Alexandra’s expertise and leadership in action as she explores new opportunities, fosters partnerships, and drives business growth for Porton Pharma. Stay tuned for insightful updates on how […]

          NEW YORK, NY – On March 20th through March 23rd, 2023, Midtown New York City was home to the 95th Annual DCAT Week, one of the world’s largest and highly recognized and attended business events for the pharmaceutical industry. During the 4-day event, hundreds of member companies engage in high-level

Porton’s recognition by Roche is a testament to the high-quality service and technical expertise that comes with working with a leading global end-to-end CDMO. Shanghai China (December 16, 2022) – Porton Pharma Solutions (hereinafter referred to as Porton) was recently awarded as a winner of the Roche CDMO Award 2021 in recognition of significant contribution

The year 2022 is an important milestone for Porton. Despite of the uncertainties of the external environment, we always keep in mind Porton’s mission of “Enabling public’s early access to good medicines” to overcome those challenges and ensure delivery through an agile and stable management system. In the future, we will maintain keen insights and

March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of APIs, intermediates and starting materials. This expansion project will add 2 production workshops, utilities workshop,

Chongqing China, February 10, 2022–Porton Pharma Solutions Ltd. (Porton) today announced it will expand its API CDMO production capacity with approximately RMB 260 million investment in Changshou site, Chongqing in order to capture growing market demand from our global pharmaceutical clients. There will be around 142.6m³ reactors being installed in the new workshop 301. This

Chongqing · China: On January 16, 2022, Porton Pharma Solutions Ltd. released the “2021 Annual Performance Forecast”. The company expects that revenue and net profit will continue to maintain strongly growth in the year of 2021. 2021 Annual Performance Forecast Revenue YoY Change +45%~50% We expect to achieve revenue of RMB 3,004.22 million to RMB

Subtitle: Enabling Public’s Early Access to Good Medicines On November 6, 2021, Porton Pharma Solutions Ltd. (hereinafter referred to as Porton, stock code: 300363) and Honeywell (NASDAQ code: HON) held a Signing Ceremony of Strategic Cooperation Agreement at the 4th China International Import Expo. Porton will conduct in-depth cooperation with Honeywell in intelligent manufacturing, striving